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RNA Oxidation Adducts 8-OHG and 8-OHA Change with
Ab42 Levels in Late-Stage Alzheimer’s Disease
Adam M. Weidner1,2., Melissa A. Bradley1,2., Tina L. Beckett1., Dana M. Niedowicz1,2, Amy L. S.
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Abstract
While research supports amyloid-b (Ab) as the etiologic agent of Alzheimer’s disease (AD), the mechanism of action remains
unclear. Evidence indicates that adducts of RNA caused by oxidation also represent an early phenomenon in AD. It is
currently unknown what type of influence these two observations have on each other, if any. We quantified five RNA
adducts by gas chromatography/mass spectroscopy across five brain regions from AD cases and age-matched controls. We
then used a reductive directed analysis to compare the RNA adducts to common indices of AD neuropathology and various
pools of Ab. Using data from four disease-affected brain regions (Brodmann’s Area 9, hippocampus, inferior parietal lobule,
and the superior and middle temporal gyri), we found that the RNA adduct 8-hydroxyguanine (8-OHG) decreased, while 8-
hydroxyadenine (8-OHA) increased in AD. The cerebellum, which is generally spared in AD, did not show disease related
changes, and no RNA adducts correlated with the number of plaques or tangles. Multiple regression analysis revealed that
SDS-soluble Ab42 was the best predictor of changes in 8-OHG, while formic acid-soluble Ab42 was the best predictor of
changes in 8-OHA. This study indicates that although there is a connection between AD related neuropathology and RNA
oxidation, this relationship is not straightforward.
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Introduction
With an increase in the aging population, neurodegenerative
diseases are becoming more prevalent. The most common form of
dementia in the U.S. is Alzheimer’s disease (AD), which is
consistently in the top 10 causes of death in the elderly [1]. While
the mechanism behind the progression of this disease remains
unclear, the importance of amyloid-b (Ab) as a causative factor in
AD is well known [2]. This small peptide is accepted as triggering
the initial event that drives the disease [3]. The Ab peptide is a
product of sequential cleavage of the amyloid-b precursor protein
(APP), and it has a tendency to aggregate. The 40 amino acid
peptide (Ab40) is the most abundant form of Ab, and is not as
aggregate-prone as the less common 42 amino acid peptide (Ab42).
The 42:40 peptide ratio increases in early onset, familial AD [4],
indicating that Ab42 may play a greater role in initial pathology
than Ab40.
The peptide aggregates become more insoluble as they continue
to accumulate - a characteristic that can be discerned by sequential
extraction under progressively more denaturing conditions. This
allows for categorization of Ab by solubility, which can help
provide insights into the pathophysiology of the disease process
[5]. The aggregation process ultimately leads to mature amyloid
fibrils which form deposits known as amyloid plaques. Amyloid
plaques are found in two different forms: diffuse plaques (DPs) and
neuritic plaques (NPs). DPs lack a dense core and are associated
with normal aging. NPs possess an amyloid core, associate with
dystrophic neurites [6], and increase in AD [7]. NPs, coupled with
tangles of hyperphosphorylated tau (neurofibrillary tangles
(NFTs)), are the basis of an AD diagnosis in postmortem tissue [8].
Apart from Ab accumulation, many other factors may
contribute to the disease process. An increase in oxidative stress
found in the form of oxidized DNA, RNA, and protein adducts
may also contribute to the progression of the disease [9,10]. The
occurrence of nucleotide oxidation has the greatest potential for
long-term, pathophysiologic consequences, as nucleotide muta-
tions may result in incorrect synthesis of numerous proteins
repeated over the life of the cell. For example, 8-hydroxyguanine
(8-OHG) can incorrectly base pair with adenine and introduce
mutations during DNA synthesis [11]. The effects of oxidative
stress on DNA has been focused on more than RNA, even though
RNA may be more vulnerable to oxidative insults than DNA given
its generally single-stranded state and accessibility to the oxidant-
producing mitochondria [12]. RNA oxidation is increased in AD
[12,13] and certain adducts are more abundant than others. The
most commonly quantified nucleotide adducts include 8-OHG, 8-
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hydroxyadenine (8-OHA), 5-hydroxycytosine (5-OHC), 2,6-di-
amino-4-hydroxy-5-formamidopyrimidine (fapyguanine), and 4,6-
diamino-5-formamidopyrimidine (fapyadenine) [14,15], all of
which are found in both DNA and RNA. Determining the role
of these adducts in AD is important to understanding the
progression of the disease.
Despite studies of RNA oxidation in various neurodegenerative
diseases [12,16,17], few studies have attempted to relate oxidation
with Ab. Furthermore, variations between studies in methodology,
as well as differences in attributes such as post mortem interval
(PMI), brain region, and subject population make it difficult to
determine the relative importance of different RNA adducts in the
progression of the disease, and how these adducts may relate to
other aspects of AD neuropathology. In this study, we performed a
systematic analysis of multiple forms of Ab and RNA adducts
across several brain regions in a well-characterized cohort of late
stage AD cases and non-cognitively impaired control cases.
Materials and Methods
Ethics Statement
Human tissue collection and handling conformed to Public
Health Service and University of Kentucky Institutional Review
Board guidelines, including written informed consent from all
participants.
Tissue Collection
Tissue samples were obtained from the Alzheimer’s Disease
Center at the University of Kentucky. All subjects were assessed
using our standard neuropsychological test battery. Details of
subject monitoring have been described previously [18]. Control
subjects (N= 10) were age-matched to AD subjects (N= 12), with
similar post mortem intervals (PMI) for both groups (see Table 1
for demographic statistics). Autopsy methods and quantitative
neuroanatomy measures have been previously published [19].
Briefly, brain weight was determined at time of autopsy and a
neuropathological evaluation was performed. Samples from four
disease-affected areas (Brodmann’s Area 9, the hippocampal
formation, the inferior parietal lobule, and the superior and
middle temporal gyri) and one disease-unaffected region (cerebel-
lum) were used for the analysis.
Measurement of Ab
We used a well-known method of serial extraction and
quantification of Ab based on solubility [20]. Briefly, tissue was
homogenized via polytron in PBS (pH 7.4; 1.0 mL/200 mg wet
tissue weight) with a complete protease inhibitor cocktail (PIC,
Amresco; Solon, OH) and centrifuged at 20,8006 g for 30 min at
4uC. The supernatant (PBS-soluble pool) was collected and the
remaining pellet was sonicated (1060.5 sec pulses at 100 W,
Fisher Sonic Dismembrator, Fisher; Pittsburgh, PA) in 2% (w/v)
SDS with PIC and centrifuged as above at 14uC. This supernatant
(SDS-soluble pool) was collected, and the pellet was sonicated a
final time in 70% (v/v) formic acid, and then centrifuged at
20,8006 g for 60 min at 4uC. The remaining supernatant fraction
was collected (FA-soluble pool). All samples were stored at 280uC
until time of assay.
Quantification of total Ab was performed using a two-site
sandwich ELISA [21], whereas oligomeric Ab was quantified
using a single-site sandwich ELISA (4G8/4G8) [22]. Immulon
4HBX plates (Nunc; Rochester, NY) were coated with 0.5 mg/well
antibody Ab9 (Ab 1–16, two-site ELISA) or 4G8 (Ab 17–24,
single-site ELISA; Covance; Princeton, NJ) and incubated
overnight at 4uC [23,24]. Wells were blocked with SynblockH
(AbD Serotec; Oxford, UK) according to manufacturer’s direc-
tions. Standard curves were prepared using synthetic Ab peptide
(rPeptide; Bogart, GA). PBS samples were diluted 1:4 in Antigen
Capture (AC) buffer (20 mM Na3PO4, 0.4% Block Ace (AbD
Serotec), 0.05% NaN3, 2 mM EDTA, 0.4 M NaCl, 0.2% BSA,
0.05% CHAPS, pH 7). SDS samples were diluted between 1:20
and 1:100 in AC buffer, and formic acid samples were first
neutralized 1:20 in TP buffer (1.0 M Tris base, 0.5 M Na2HPO4)
then further diluted between 1:5 and 1:20 in AC buffer. Standards
and samples were run at least in duplicate and were incubated at
4uC overnight. Biotinylated detection antibodies were Ab13.1.1
(Ab40-end specific), 12F4 (Ab42-end specific; Covance) or 4G8
(Ab17–24), followed by the addition of NeutrAvidin-HRP (Pierce
Biotechnologies; Rockford, IL). Colorimetric detection used
3,39,5,59-tetramethylbenzidine reagent (TMB; Kirkegaard & Perry
Laboratories; Gaithersburg, MD). The reaction was stopped via
acidification (6% o-phosphoric acid) and read using a BioTek
Powerwave XS (Winooski, VT) plate reader at 450 nm.
Pittsburgh compound B (PiB) binding in post-mortem human
specimens has been used to detect fibrillar Ab, the most advanced
form of Ab aggregation [25]. The degree of PiB binding may
differentiate between detrimental and benign fibrillar Ab aggre-
gates [26]. Quantification of PiB binding in the PBS homogenate
was performed as described by Rosen et al. [26]. Homogenate
(5 ml) was added to 250 ml PBS in a 96-well polypropylene plate on
ice. Twenty microliters of this diluted homogenate was then
transferred to another plate in triplicate. In two wells, 200 ml of
1.2 nM 3H-PIB in PBS+5% (v/v) EtOH was added to measure
total binding. In the third well, 1.2 nM 3H-PIB in PBS+5% (v/v)
EtOH plus 1 mM BTA-1 was added to correct for non-specific
binding. The contents of the plate were transferred to a
Multiscreen-FB (GF/B) (Millipore; Billerica, MA) plate and
washed with PBS. The glass fiber filters were soaked overnight
in Budget-Solve (RPI; Mount Prospect, IL) scintillation fluid,
counted, and standardized to the BTA-containing wells.
Table 1. Summary of Subject Demographic Data.
Neuropathologic Variables
Sex Age (y) Brain Weight (g)
Post Mortem
Interval (h) MMSE Score
Neurofibrillary
Tangles
Neuritic
Plaques
Diffuse
Plaques
Control 1M/9F 90.065.6 11346118 2.960.6 28.061.6 1.563.8 0.461.0 1.362.1
AD 2M/10F 83.066.7 10406104 3.060.7 6.967.2* 49.3617.4* 17.765.5* 32.3611.1*
All AD cases were Braak stage VI; control cases were all stage II or less. Neuropathologic variables were averaged across several disease affected brain regions (inferior parietal
lobule, midfrontal gyrus, superior and middle termporal gyri, hippocampal area CA1, and the subiculum). Values are mean +/2 standard deviation;
*=p,0.01 relative to control cases, adjusted for multiple comparisons.
doi:10.1371/journal.pone.0024930.t001
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RNA isolation and Sample Preparation
RNA isolation was performed using TRIzolH (Invitrogen;
Carlsbad, CA) as described in Rio et. al. [27]. Briefly, tissue was
homogenized in TRIzolH (1 mL/100 mg; Invitrogen) as per
manufacturer’s instructions, followed by an additional phenol-
chloroform extraction and ethanol precipitation.
To prepare samples for gas chromatography (GC), we used a
procedure similar to that described in Wang et al. [28]. RNA (10–
20 mg) was analyzed by GC/mass spectrometry (GC/MS) with
selective ion monitoring (see below). Stable-labeled oxidized base
internal standards (10 nmol) including 8-[8-13C,7,9-15N2] hydro-
xyguanine, 8-[8-13C,6,9-diamino-15N2] hydroxyadenine, 5-
[2-13C,1,3-15N2] hydroxycytosine, [formyl-
13C, diamino-15N2]
fapyadenine and [formyl-13C, diamino-15N2] fapyguanine (Cam-
bridge Isotope Laboratories; Andover, MA) were added to
lyophilized RNA samples and were hydrolyzed with 250 mL
90% formic acid at 145uC for 30 min in evacuated 5 mL conical
glass tubes. After hydrolysis, samples were lyophilized and
derivatized with a mixture of N,O-bis-trimethylsilyltrifluoroaceta-
mide/pyridine (1:1) at 25uC for 2 h in evacuated tubes. The
derivatized products were dried under a constant stream of
nitrogen using an OA-SYS heating system (Organomation
Associates; Berlin, MA). Derivatized RNA base adducts were
dissolved in 20 mL N,O-bis-trimethylsilyltrifluoroacetamide and
transferred to GC autosampler vials.
Gas chromatography/mass spectrometry with selective
ion monitoring analysis
Derivatized samples (2 mL) were analyzed using an Agilent
7800A gas chromatograph (Agilient Technologies; Santa Clara,
CA) on an HP 5 ms capillary column (0.25 mm internal
diameter, 0.25 mm film thickness, and 30 m length; Hewlett
Packard, Palo Alto, CA, USA) as previously described [28].
Chromatographic parameters were as follows: ultra high purity
helium was used as a carrier gas at an inlet pressure of 11.8 psi,
and used constant flow and split-less mode. The injection port
was maintained at 250uC. The initial temperature was held for
2 min at 100uC after sample injection with the following ramps:
ramp 1, 100–178uC at 3uC/min; ramp 2, 178–181uC at 0.3uC/
min; ramp 3, 181–208uC at 3uC/min and ramp 4, 208–280 at
10uC/min. The final temperature was maintained for 2 min, the
run time was 56.2 min for each sample, and the temperature of
the ion source inside the mass spectrometer was 180uC.
Derivatized nitrogenous base spectra were acquired in selective
ion monitoring mode at m/z ratios of 331 5-[2-13C,1,3-15N2]
hydroxycytosine and m/z 328 5-hydroxycytosine; m/z 357
[formyl-13C, diamino-15N2] fapyadenine and m/z 354 fapyade-
nine; m/z 355 8-[8-13C,6,9-diamino-15N2] hydroxyadenine and
m/z 352 8-hydroxyadenine; m/z 445 [formyl-13C, diamino-
15N2] fapyguanine and 442 fapyguanine: and m/z 443 8-
[8-13C,7,9-15N2] hydroxyguanine and m/z 440 8-hydroxygua-
nine. Instrument response plots of the integrated peaks of stable
isotope-labeled analyte signal added were determined over a
range of 0.5 nmol to 10.0 nmol per stable isotope-labeled
analyte. Plots of instrument response versus concentration
showed positive significant correlations for stable label isotopes:
5-[2-13C,1,3-15N2] hydroxycytosine (r = 0.94): [formyl-
13C,
diamino-15N2] fapyadenine (r=0.97): 8-[8-
13C,6,9-diami-
no-15N2] hydroxyadenine (r=0.91); [formyl-
13C, diamino-15N2]
fapyguanine (r=0.92); 8-[8-13C,7,9-15N2] hydroxyguanine
(r=1.00). The integrated area of each analyte signal was
normalized with respect to the integrated area of the corre-
sponding internal standards for all samples and corrected based
on instrument response plots.
Data Analysis
We used a reductive approach to determine relative significance
(Figure 1). A Spearman correlation was used to determine the
relationships between the five RNA adducts and the other
measures of pathology across multiple brain regions. These
pathology measures included NFTs, DPs, NPs, PiB binding
(fibrillar Ab), Ab oligomers, and the various soluble pools of Ab. A
multivariate analysis (which included gender as a variable, and
both PMI and age as covariates) was performed to determine
which variables were significantly different in the AD-affected
individuals. These variables were analyzed by stepwise multiple
regression to determine if any variable or combination of variables
were associated with changes in the RNA adducts of interest.
Known differences in group demographics were verified by
Student’s t-test or Mann-Whitney U-test where appropriate,
adjusting for multiple testing using the Holm-Bonferroni method
[29]. All data were analyzed using PASWH 18 (IBM; Somers, NY).
Graphs and regression lines were calculated and produced in
SigmaPlotH (Systat; San Jose, CA).
Figure 1. Flowchart depicting the steps comprising the data analysis. A directed analysis of the data was used to reduce the large data set
to its significant components. A multivariate analysis determined which variables were significantly different in AD using PMI and age as covariates
and gender as a variable; only significant variables were included in further analysis. A Spearman correlation was used to determine the relationships
between the five RNA adducts of interest and the other measures of AD pathology. Finally, these significant variables were analyzed by stepwise
multiple regression to determine if they predicted the changes in the RNA adducts.
doi:10.1371/journal.pone.0024930.g001
RNA Oxidation Changes in Alzheimer’s Disease
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Results and Discussion
While oxidatively modified RNA is increased in AD [12,13],
when compared to both oxidatively modified DNA and protein,
RNA is understudied. However, RNA may be a better marker of
oxidative stress (e.g. more susceptible to damage) in the AD brain.
In spite of several studies documenting changes in RNA oxidation
in the AD brain, it is not clear which adducts are more important.
It can be difficult to compare reported results because of variations
in methods, tissue sample quality, and brain regions among
separate studies. In this study, we took a systematic approach to
answer these questions.
Using GC/MS, we quantified five forms of oxidatively modified
RNA in the AD brain (8-OHG, 8-OHA, 5-OHC, fapyadenine,
and fapyguanine). We analyzed the relationship between these
RNA adducts and the common neuropathological markers used to
diagnose AD (neuritic plaques, diffuse plaques, and neurofibrillary
tangles). A correlational analysis of the data did not indicate any
significant relationships between any of these markers and any of
the five RNA adducts (p.0.1 in all cases). This was true across all
cases, even when the analysis was restricted to AD cases alone.
Therefore, although all three markers of neuropathology are
significantly higher in the AD cases, they are independent of RNA
oxidation.
We performed a multivariate analysis to determine if any of the
RNA adducts differed between AD cases and controls. We did not
detect any difference in RNA adducts between disease states in the
cerebellum. This was not unexpected, as the cerebellum does not
typically exhibit substantial pathology in AD. An analysis
restricted to the disease- affected regions (Brodman’s Area 9,
hippocampus, inferior parietal lobule, and the superior and middle
temporal gyri) showed that two of the five RNA adducts changed
in AD cases when compared to controls (Figure 2). 8-OHA
lesions increased [F(1,16) = 5.12, p,0.04], whereas 8-OHG
decreased [F(1,16) = 4.66, p,0.05].
Abundant oxidation of guanine is attributed to its high
oxidation potential. However, the oxidation potential of guanine
has been shown to be modulated based on location (59 vs. 39),
stacking base interactions, existing mismatched base pairing, and
flanking nucleic acid sequence in double-stranded DNA
[30,31,32]. To date, modulation of oxidation potentials have not
been evaluated in an RNA model similar to polyadenylated
mRNA. The possibility of modulated oxidation potentials and the
abundance of adenine may contribute to the dichotomy observed
in these RNA adducts. Alternatively, this may represent a
temporal process, whereby 8-OHG accumulates earlier during
the disease and then declines, while 8-OHA increases later in the
disease. Evidence from Nunomura et. al. [31] suggests Ab
accumulation directly reduces oxidative adducts, resulting in
decreased 8-OHG levels with increased pathology. Since the
current study only includes late stage AD cases, answering this
question would require an examination of multiple RNA adducts
across several brain regions in very early or preclinical AD cases.
As expected, a multivariate analysis showed increased total Ab
in AD, in all regions except the cerebellum [F(1,16) = 5.08,
Figure 2. 8-OHG and 8-OHA change in opposite directions in
the late-stage AD brain. The 8-OHG adduct decreased (p = 0.046) in
the disease state, whereas the 8-OHA adduct increased in AD brain
(p = 0.038). Data are expressed as the number of oxidatively modified
bases per 1000 bases of total RNA. The analysis included gender, age
and PMI. Values were averaged over several disease-affected brain
regions (c.f. Table 1); no significant changes were seen in cerebellum.
NCI: No Cognitive Impairment; AD: Alzheimer’s disease. Rotated
Hourglass: mean.
doi:10.1371/journal.pone.0024930.g002
Figure 3. Oxidation adducts are modeled by single but
separate pools of Ab. Using multiple stepwise regression, the
decrease in 8-OHG was correlated to SDS-soluble Ab42 (top; adj-
R2 = 0.257; p,0.01) while the increase in 8-OHA lesions was correlated
to formic acid-soluble Ab42 (bottom; adj-R
2 = 0.141; p,0.05). Data are
expressed as the number of oxidatively modified bases per 1000 bases
of total RNA. Open Symbol: NCI; Closed Symbol: AD.
doi:10.1371/journal.pone.0024930.g003
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p,0.04]. The amount of post-mortem PiB binding was also
significantly increased [F(1,16) = 17.84, p,0.001]. Surprisingly,
we did not find higher total amounts of oligomeric Ab in the AD
cases compared to the control cases [F(1,16) = 2.45, p,0.14]. This
was unexpected, since there is typically an abundance of
oligomeric Ab in the AD brain, which can be visualized by a
variety of methods [25,33]. Since our assay primarily measures
larger oligomers (.40 kDa) [22], this may indicate that the
increase in oligomeric Ab in AD is mostly smaller forms that we do
not detect. Ab oligomers cause cell death and changes in
morphology and function [34,35], and recent reports show that
Ab dimers may play a major role in AD pathophysiology [36].
Further study is required to assess the relative contribution of
smaller oligomeric species to RNA oxidation in the AD brain.
Ab has been suggested as a prime etiological agent of AD, and
thus may relate to or even drive nucleotide oxidation [2]. We
performed a stepwise multiple regression analysis to determine if
any pools of Ab were linked to changes in the two RNA adducts
(8-OHA and 8-OHG). For the analysis, we deconvoluted the total
Ab measure to its individual component measures (PBS-, SDS- or
FA-soluble Ab40 and Ab42) to identify the major contributor to
disease-associated variance. We have shown previously that the
solubility of the Ab peptide is an important variable in AD [20,37].
The PBS-soluble fraction primarily contains monomeric and low-
weight Ab oligomers, the SDS-soluble fraction contains higher
order Ab multimers and is associated with the amount of DPs, and
the FA-soluble fraction contains highly insoluble accumulated Ab
associated with NPs [20].
Neither fibrillar Ab, as measured by PiB binding, nor any pools
(PBS-, SDS- or FA-soluble) of Ab40 were significantly related to the
changes in 8-OHA or 8-OHG in AD. This was not unexpected, as
the Ab40 species is generally accepted as the less toxic form, and is
less implicated in the disease process. However, the disease-related
changes in the two RNA adducts were associated with SDS-soluble
and FA-soluble levels of Ab42: SDS-soluble Ab42 was inversely
related to 8-OHG [F(1,20) = 8.28,p,0.01] and FA-soluble Ab42
was directly related to 8-OHA [F(1,20) = 4.44,p,0.05] (Figure 3).
As might be expected from the Spearman correlational analysis, no
form of Ab predicted the amount of the other three RNA adducts
(fapyadenine, fapyguanine, or 5-OHC) in the brain; AD neuro-
pathologic markers (DPs, NPs, NFTs) also did not predict the
amount of these adducts.
The reason behind the opposite directionality of these adducts is
unclear. However, the fact that they relate to different soluble
levels of Ab42 may indicate that the adducts form at different
stages of AD progression, as the amount of FA-soluble Ab
increases more in late stage disease [20]. Of the disease-affected
brain regions studied, the RNA adducts in the hippocampus had
the strongest correlation to disease effect. The hippocampus is an
early structure which is affected in the disease process, and exhibits
severe atrophy in later stages of the disease [38]. It is possible that
8-OHG increases here initially in the disease, but then declines. If
this is true, then an evaluation of an expanded cohort of subjects in
earlier disease states such as preclinical AD and mild cognitive
impairment would be needed to confirm this.
Of the five RNA adducts analyzed, only 8-OHG and 8-OHA
were significantly altered in late stage AD, and each related to a
single extractable pool of Ab42: 8-OHG was related to SDS-
soluble Ab42, and 8-OHA was related to FA-soluble Ab42. These
adducts were not related to other pools of Ab nor to any standard
neuropathological markers of AD. Interestingly, while 8-OHA
increased in late-stage AD, 8-OHG decreased. It is possible that
the different behavior of the two RNA adducts is explained by a
temporal mechanism. Our examination of only non-cognitively
impaired subjects and late-stage AD cases omits a time span where
an increase in 8-OHG may occur and then decline. Indeed, 8-
OHG is increased in several disease affected regions in earlier
stage AD [39], including the hippocampus [40]. The decrease of
8-OHG may be explained by the extensive cell death which occurs
in late-stage AD, although this can be difficult to deal with
analytically [41,42]. The decrease may also be a result of the direct
influence of Ab as a compensatory mechanism [31]. This work
raises several interesting avenues for mechanistic studies. The
specific relationship between toxic Ab aggregates and problematic
RNA derivatives remains to be explored.
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